Contacts : Bob YedidLife Science Advisors(646)597-6989 firstname.lastname@example.orgSOURCE Intec Pharma Ltd.
JERUSALEM, March 5, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC), a clinical-stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill™ platform technology, today announced that the Company's officers will provide a corporate overview at four investor presentations in March 2018. John Kozarich, Chairman, will present at the 30 th Annual ROTH Conference, and Jeffrey Meckler, Chief Executive Officer and Vice Chairman, will present at the Barclays Global Healthcare Conference, the Oppenheimer 28 th Annual Healthcare Conference, and the Future Leaders in the Biotech Industry Conference. 30 th Annual ROTH Conference Date: Monday, March 12 at 12:30 pm PTLocation: Ritz Carlton Laguna Nigel, CARoom: Yellow Track - Salon 6Webcast: http://wsw.com/webcast/roth32/ntec/ Barclays Capital Global Healthcare Conference Date: Tuesday, March 13 at 8:30 am ETLocation: Loews Miami Beach HotelRoom: Americana Salon 1Webcast: https://cc.talkpoint.com/barc002/031318a_as/?entity=97_BDI7WFT Oppenheimer 28 th Annual Healthcare Conference Date: Tuesday, March 20 at 8:35 am ETLocation: The Westin New York Grand CentralRoom: Track 2Webcast link: https://www.veracast.com/webcasts/opco/healthcare2018/55102599689.cfm Future Leaders in the Biotech Industry Date: Friday, March 23 at 11:00 am ETLocation: Millennium Broadway HotelRoom: 302/303 About Intec Pharma Ltd. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.